Program
GnRH Antagonist SHR7280
Also written as “SHR7280 tablets”, “SHR7280” and “SHR7280;Ganirelix Acetate Injection simulant”.
In Jiangsu HengRui Medicine’s pipeline, GnRH
. Its studies are mostly in Endometriosis · Leiomyoma · Prostatic Neoplasms, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 101 open or running | phase 3since Jun 16, 2022 | May 21, 2020 | none ahead |
- Named in Jiangsu HengRui Medicine’s own pipeline as
SHR7280
, phase 4, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 21, 2020First study: phase 2 study in EndometriosisFirst studyNCT04417972 · 179 enrolled · China
- Aug 31, 2020Phase 1 study in Healthy SubjectsNCT04554043 · 118 enrolled · China
- Jul 29, 2021Phase 1 study in Hormone Sensitive Prostate CancerNCT04995042 · 12 enrolled · China
- Sep 29, 2021Phase 2 study in Female Subjects Undergoing COH in ART to Prevent Early OvulationNCT05082233 · 85 enrolled · China
- Jun 16, 2022Phase 3 study in Uterine Fibroids With MenorrhagiaNCT05442827 · 357 planned · China
- May 11, 2023Phase 1 study in EndometriosisNCT05868057 · 16 enrolled · China
- Aug 9, 2023Phase 3 study in Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early OvulationNCT05994378 · 317 enrolled · China
- May 7, 2024Phase 1 study in Assisted ReproductionNCT06408948 · 6 enrolled · China
- Apr 22, 2025Phase 1 study in EndometriosisNCT06949124 · 20 enrolled · China
- May 6, 2025Phase 1 study in EndometriosisNCT06969664 · 16 enrolled · China
TargetBeta
“GnRH”the company's pipeline, read by Claude · source
“An orally bioavailable gonadotropin-releasing hormone (GnRH) receptor antagonist, with potential hormone production inhibitory activity. Upon oral administration, GnRH antagonist SHR7280 competes with GnRH for receptor binding and inhibits GnRH receptor signaling in the anterior pituitary gland, …”NCIt, read by Claude
Other programs on GNRHR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Leuproliderule | Takeda | phase 4 | 39 |
| triptorelinrule | Ipsen | phase 4 | 21 |
| Goserelinrule | AstraZeneca | phase 4 | 14 |
| linzagolixrule | Kissei Pharmaceutical | phase 3 | 14 |
| Gonadotropin-Releasing Hormonerule | Ferring Pharmaceuticals | phase 3 | 5 |
| leuprolide mesylaterule | foresee-pharmaceuticals-co-ltd | phase 3 | 3 |
Studies
All 10 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06969664Endometriosis · China | 1 | Completed | Jul 5, 2025 | 16 |
| NCT06949124Endometriosis · China | 1 | Completed | Jun 5, 2025 | 20 |
| NCT06408948Assisted Reproduction · China | 1 | Completed | Jul 6, 2024 | 6 |
| NCT05994378Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation · China | 3 | Completed | May 2, 2025 | 317 |
| NCT05868057Endometriosis · China | 1 | Completed | Jun 9, 2023 | 16 |
| NCT05442827Uterine Fibroids With Menorrhagia · China | 3 | Recruiting | Jun 1, 2026 | 357 |
| NCT05082233Female Subjects Undergoing COH in ART to Prevent Early Ovulation · China | 2 | Completed | Aug 3, 2023 | 85 |
| NCT04995042Hormone Sensitive Prostate Cancer · China | 1 | Completed | May 24, 2023 | 12 |
| NCT04554043Healthy Subjects · China | 1 | Completed | Sep 28, 2021 | 118 |
| NCT04417972Endometriosis · China | 2 | Completed | May 14, 2024 | 179 |
How it is read
Names in the registry
- “SHR7280 tablets”, 4 entries
- “SHR7280”, 3 entries
- “SHR7280;Ganirelix Acetate Injection simulant”, 1 entry
- “SHR7280 Tablets”, 1 entry
- “SHR7280 Tablet”, 1 entry
Codes read as this program: SHR7280.
Conditions, from the studies’ own filings
- Endometriosis, 4 studies
- Leiomyoma, 1 study
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.